We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Show more
DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
A healthcare company based out of North Carolina is turning heads so far during Tuesday’s session after the company announced that it plans to submit its Dordaviprone for To read the full...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -5.52325581395 | 3.44 | 3.8 | 3.25 | 1475220 | 3.57890286 | CS |
4 | 0.2956 | 10.0054156512 | 2.9544 | 3.8 | 2.705 | 1696537 | 3.20751187 | CS |
12 | 2.3789 | 273.091493514 | 0.8711 | 3.8 | 0.8101 | 4495871 | 2.62121088 | CS |
26 | 2.44 | 301.234567901 | 0.81 | 3.8 | 0.75 | 2218613 | 2.44503522 | CS |
52 | 2.23 | 218.62745098 | 1.02 | 3.8 | 0.75 | 1283367 | 2.26523409 | CS |
156 | -2.72 | -45.5611390285 | 5.97 | 6.52 | 0.75 | 1547373 | 2.25702627 | CS |
260 | 1.11 | 51.8691588785 | 2.14 | 11.5696 | 0.75 | 1243990 | 3.1876298 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions